Oxytocin occupies a strange position in this category: unlike almost everything else covered here, it’s a long-approved pharmaceutical, used in obstetric settings to induce or strengthen labor contractions. The research-compound market sells it for an entirely different set of reasons, rooted in its separate, better-known reputation as a “bonding hormone.”

The Approved Use, Briefly

Oxytocin’s FDA approval and clinical dosing protocol are specific to obstetric use, administered in a clinical setting with monitoring — a context that shares almost nothing with self-administered research-compound use.

“It being an approved drug for one thing gets borrowed as credibility for a completely different, much less settled claim.”

— a behavioral neuroscientist who has studied oxytocin’s social effects

The Social-Bonding Research Base

A real and substantial body of research has examined oxytocin’s role in social bonding, trust, and attachment behavior, largely using intranasal administration in controlled study settings — interesting science, but with mixed and sometimes non-replicating results across studies, a point researchers in the field have themselves raised.

Why Approved Elsewhere Doesn’t Mean Studied for This

Oxytocin being a real, approved drug for one purpose doesn’t transfer evidence to an unrelated purpose. The social-cognition research has its own separate, and notably mixed, track record.